Requirement 1: includes (I) an effective number of cancer therapeutics and (II) an effective number of immunotherapeutics capable of activating a human plasticized mucus jet cell, membrane cell or NK cell, or a combination of both. 19. Claim 9: the combination of claim 8. The antibody was selected from the following group: rituxan (rituximab),Herceptin (trastuzumab)Erbitux (cetuximab)Vectibix (Panitumumab)Arzerra (Ofatumumab)Benlysta (belimumab)Yervoy (ipilimumab)Perjeta (pertuzumab), tremelimumab, nivolumab, dachetuzumab, urelumab, mpd3280 a, lambrolizumab, blinatummab, ct-011, mk-3475, bms-936559, med14736, msb010718c and margetuximab (mgah22). 13. Claim 15: any combination of claims 1 to 13, including: (a) single chain RN (RNCs),Preferably orn02, orn06, sspoly (U),ssRNA40 SSRNA41 ssRNA-DR o Poly (dT)O (b) similar receiver configuration, preferably cl075, cl097, cl264, cl307, gardiqimov, loxoribina, imquimod or resquimod. Claim 16: any combination of claims 1 to 13, in which the immunotherapy preparation has a formula structure (1),a. Dashed line indicates connected or unlinked； X is s-nr1；R¹ is -W⁰-W¹-W²-W³-W⁴；W830404 is a link, asphalt, aluminum, asphalt, alcoxi o-quil-s-quil -；W1 is a link, O--it is life.Where R2 is hydrogen, coke or sulphite； W2 is a link, or--C (o) ---C (S) - o -S (O) -W3 is a link, - N3 -.R3 is hydrogen, tar or calcium； w830808 is hydrogen, tar, acyl chloride, asphalt, propoxy, cyclopentyl compound, arilo, ariloxi, isopropene or isopropene, which can be replaced by one or more substitutes selected from hydroxyl, alcoxi, tar, alquenilo and hydrocarbon, Bike, arilo, straight, straight, straight, straight,1. Nitro, - tar hydroxy, - tar arilo, - tar heterogeneous, - tar isomerization, - o-r8308；-O-tar-r8308；-Tar-o-r8308；--C (O) -R-Tar-c (o) - r8308；-Tar-c (o) - o-r8308；--C (O) -O-R-S-R83088；--S (O) -R--NH-S (O) -R-Tar-s-r8308；-Tar-s (o) 83228r8308；-NHR8308；-8308； 83088；-NH tar r8308；Halogen, - CN, - no8322y-sh, wherein r83088 is independent hydr
